Johnson & Johnson upgraded at RBC Capital As noted earlier, RBC Capital upgraded Johnson & Johnson to Outperform from Sector Perform. The firm expects the company's pharmaceutical franchise to continue to deliver above industry average revenue growth, and it predicts that the company will continue to have operating leverage, enabling its EPS to surpass consensus levels over the next several years. Target to $104 from $88.
News For JNJ From The Last 14 Days
Check below for free stories on JNJ the last two weeks.